Express News | Imunon Announces Phase 1 Trial Results For IMNN-101 DNA Vaccine Showing 2-4x Antibody Increase Vs. Omicron Variant With No Serious Adverse Effects In 24 Participants; Vaccine Demonstrated Cross-Reactivity With New Variants

BenzingaFeb 26 08:08 ET

Immunome to Present at Upcoming March Conferences

BusinesswireFeb 25 08:00 ET

Aro Biotherapeutics Appoints President And CEO As Board Chair; Appoints Purnanand Sarma As CEO

BenzingaFeb 11 08:33 ET

Positive Week for Immunome, Inc. (NASDAQ:IMNM) Institutional Investors Who Lost 53% Over the Past Year

Simply Wall StFeb 6 07:11 ET

Insider Purchase: President and CEO of $IMNM Buys 150,000 Shares

Quiver QuantitativeFeb 3 21:15 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BenzingaJan 30 07:07 ET